Welcome to our dedicated page for Medpace Holdings news (Ticker: MEDP), a resource for investors and traders seeking the latest updates and insights on Medpace Holdings stock.
Medpace Holdings, Inc. (Nasdaq: MEDP) is a scientifically driven, global, full-service clinical contract research organization (CRO) that regularly issues detailed financial and operational updates. This news page aggregates Medpace news, including quarterly and annual earnings releases, conference call announcements, and other disclosures that matter to investors following MEDP stock and the clinical research sector.
Medpace’s press releases focus on revenue trends, GAAP net income, EBITDA and EBITDA margin, backlog levels, and net new business awards, along with net book-to-bill ratios. The company also provides financial guidance ranges for upcoming periods, discussing expected revenue, net income, and EBITDA, as well as assumptions related to tax rates, interest income, and diluted share counts. These updates help readers understand how demand for Medpace’s Phase I–IV clinical development services is evolving over time.
In addition to earnings results, Medpace frequently announces the dates and times of upcoming earnings releases and conference calls, along with webcast access details and references to supplemental slide presentations in its investors section. The company’s news also touches on capital allocation decisions, such as stock repurchase program authorizations and remaining repurchase capacity, and occasionally on financing arrangements, as reflected in filings related to its unsecured credit facility.
Because Medpace operates as a global CRO serving biotechnology, pharmaceutical and medical device sponsors, its news flow offers insight into the broader outsourcing environment for clinical research and development. Investors, analysts, and industry observers can use this page to review historical announcements, monitor new earnings releases, and track changes in guidance, backlog, and booking trends over time.
Medpace Holdings (MEDP) has announced it will release its fourth quarter and fiscal year 2024 financial results after market close on Monday, February 10, 2025. The company will host a conference call on Tuesday, February 11, 2025, at 9:00 a.m. ET to discuss the results.
Participants must pre-register through a provided link to join the conference call. A webcast of the call will be available in the 'Investors' section of Medpace's website, with a replay accessible approximately one hour after the call ends. A supplemental slide presentation will also be available on the website before the call begins.
Medpace Holdings, Inc. (MEDP) reported strong financial results for Q3 2024. Revenue increased 8.3% to $533.3 million, with a backlog conversion rate of 18.2%. GAAP net income rose to $96.4 million, or $3.01 per diluted share, representing a net income margin of 18.1%. EBITDA grew 31.7% to $118.8 million, with an EBITDA margin of 22.3%.
Key highlights include:
- Net new business awards of $533.7 million
- Net book-to-bill ratio of 1.00x
- Backlog increased 8.8% to $2,927.4 million
- Cash and cash equivalents of $656.9 million
For full-year 2024, Medpace forecasts revenue between $2.090 billion and $2.130 billion, representing growth of 10.8% to 12.9% over 2023.
Medpace Holdings, Inc. (Nasdaq: MEDP) has announced that it will release its third quarter 2024 financial results after the market closes on Monday, October 21, 2024. The company will host a conference call the following morning, Tuesday, October 22, 2024, at 9:00 a.m. ET to discuss these results.
To participate in the conference call, interested parties must register in advance using the provided link. Upon registration, participants will receive a confirmation email with dial-in details and a unique PIN. The company recommends joining 10 minutes before the event start.
A webcast of the call will be available in the "Investors" section of Medpace's website, with a replay accessible approximately one hour after the call ends. Additionally, a supplemental slide presentation will be available on the website prior to the call.
Medpace Holdings, Inc. (MEDP) reported strong financial results for Q2 2024. Revenue increased 14.6% to $528.1 million, with a backlog conversion rate of 18.2%. GAAP net income rose to $88.4 million, or $2.75 per diluted share, up from $61.1 million in Q2 2023. The company's net income margin improved to 16.7%, while EBITDA grew 34.2% to $112.3 million.
Medpace's backlog increased 13.7% to $2,924.9 million, and net new business awards were $551.0 million, resulting in a net book-to-bill ratio of 1.04x. The company updated its 2024 financial guidance, forecasting revenue between $2.125 billion and $2.175 billion, representing 12.7% to 15.3% growth over 2023.
Medpace Holdings will announce its Q2 2024 financial results post-market on July 22, 2024.
A conference call to discuss the results is scheduled for July 23, 2024, at 9:00 a.m. ET.
Participants must register in advance via a provided link, and step-by-step access details will be sent by email.
The call can also be accessed through a webcast on Medpace's investor site, where a replay and supplemental slide presentation will be available post-call.
Medpace is traded under the ticker MEDP on Nasdaq.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.